SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form 4 - Statement of changes in beneficial ownership of securities:
SEC Accession No. 0001725160-24-000004
Filing Date
2024-01-03
Accepted
2024-01-03 20:21:08
Documents
1
Period of Report
2024-01-02

Document Format Files

Seq Description Document Type Size
1 FORM 4 wk-form4_1704331256.html 4  
1 FORM 4 wk-form4_1704331256.xml 4 6136
  Complete submission text file 0001725160-24-000004.txt   7771
Mailing Address 1359 BROADWAY, SUITE 801 NEW YORK NY 10018
Business Address 1359 BROADWAY, SUITE 801 NEW YORK NY 10018 (212) 433-3791
Zentalis Pharmaceuticals, Inc. (Issuer) CIK: 0001725160 (see all company filings)

IRS No.: 823607803 | Fiscal Year End: 1231
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)

Mailing Address C/O IDEAYA BIOSCIENCES, INC. 7000 SHORELINE COURT, SUITE 350 SOUTH SAN FRANCISCO CA 94080
Business Address
Lackner Mark (Reporting) CIK: 0001777413 (see all company filings)

Type: 4 | Act: 34 | File No.: 001-39263 | Film No.: 24509407